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Actinobacillus actinomycetemcomitans plays a major role in the pathogenesis of
aggressive periodontitis. Lipopolysaccharide (LPS) derived from A. actinomycetemcom-
itans is a key factor in inflammatory cytokine generation within periodontal tissues. In this
study, we identify major mitogen-activated protein kinase (MAPK) signaling pathways
induced by A. actinomycetemcomitans LPS, Escherichia coli LPS and interleukin-1b (IL-
1b) in a murine periodontal ligament (mPDL) fibroblast cell line. Immunoblot analysis was
used to assess the phosphorylated forms of p38, extracellular-regulated kinase (ERK) and
c-jun N-terminal kinase (JNK) MAPK following stimulation with A. actinomycetem-
comitans LPS, E. coli LPS and IL-1b. IL-6 mRNA induction was detected via reverse
transcription-polymerase chain reaction, while protein levels were quantified via enzyme-
linked immunosorbent assays (ELISA). We utilized biochemical inhibitors of p38, ERK
and JNK MAPK to identify the MAPK signaling pathways needed for IL-6 expression.
Additional use of stable mPDL cell lines containing dominant negative mutant constructs
of MAPK kinase-3 and -6 (MKK-3/6) and p38 null mutant mouse embryonic fibroblast
(MEF) cells were used to substantiate the biochemical inhibitor data. Blocking p38 MAPK
with SB203580 reduced the induction of IL-6 mRNA by A. actinomycetemcomitans LPS,
E. coli LPS and IL-1b by >70%, >95% and60%, respectively. IL-6 ELISA indicated that
blocking p38 MAPK reduced the IL-6 protein levels induced by A. actinomycetemcom-
itans LPS, E. coli LPS and IL-1b by 60%, 50% and 70%, respectively. All MAPK
inhibitors significantly reduced the IL-6 protein levels induced by A. actinomycetem-
comitans LPS, E. coli LPS and IL-1b whereas only p38 inhibitors consistently reduced the
A. actinomycetemcomitans LPS, E. coli LPS and IL-1b induction of IL-6 mRNA steady-
state levels. The contribution of p38 MAPK LPS-induced IL-6 expression was confirmed
using MKK-3/6 dominant negative stable mPDL cell lines. Wild-type and p38a)/) MEF
cells provided additional evidence to support the role of p38a MAPK in A. actinomyce-
temcomitans LPS-stimulated IL-6. Our results indicate that induction of IL-6 by E. coli
LPS, IL-1b and A. actinomycetemcomitans LPS requires signaling through MKK-3-p38a
ERK, JNK and p38 MAPK in mPDL cells.
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Periodontal disease initiation and progres-
sion occur as consequences of the host
immune inflammatory response to oral
pathogens. Periodontal pathogens produce
collagenases and proteases that facilitate
extracellular matrix degradation to produce
nutrients for their growth (2). In addition,
Actinobacillus actinomycetemcomitans
and other periodontal pathogens possess
multiple virulence factors, such as leuko-
toxin, peptidoglycans, outer membrane
proteins and LPS (20), which initiate the
host inflammatory response, including the
production of host-derived inflammatory
molecules such as matrix metalloprotein-
ases (MMPs), cytokines and prostaglan-
dins (6, 7, 20). Although much effort has
been applied in the analysis of lipopoly-
saccharide (LPS)-mediated destruction of
the periodontium, little is known of the
major intracellular signaling pathways
utilized by A. actinomycetemcomitans
LPS within resident periodontal tissue
types.
Mitogen-activated protein kinases
(MAPKs) are divided into three families,
the extracellular signal-regulated kinases
(ERK-1/2), c-jun N-terminal kinase (JNK)
and p38a. Mitogens and growth factors
primarily activate ERK-1/2, whereas the
pro-inflammatory cytokines, such as inter-
leukin-1b (IL-1b) and tumor necrosis fac-
tor-a (TNF-a), and cell stress-inducing
factors, such as heat shock, ultraviolet
radiation and oxygen radicals chiefly acti-
vate JNKs and p38a. The three MAPKs
control the activation of many transcription
factors, including AP-1 (homo- or heterod-
imer of the proteins c-fos and c-jun), nuclear
factor-jB (NF-jB), or C/EBP (ccAAAT
enhances binding protein).
It is assumed that all three MAPK
families are expressed in diseased perio-
dontal tissues, although expression levels
may differ depending upon the cell types
activated and the levels of inflammation.
Within periodontally resident cells, inclu-
ding tissue macrophages and other perio-
dontal cells, MAPKs are activated chiefly
by LPS, IL-1 and TNF-a (18, 22, 27). The
p38 MAPK, most notably its p38a iso-
form, is activated mainly within cells
involved in the inflammatory process.
Activation of p38a through more proximal
signaling intermediates termed MAPK
kinases (MKK) induces synthesis of pro-
inflammatory cytokines and prostanoids
such as TNF-a, IL-1, IL-6, IL-8 and
prostaglandin E2, via direct activation of
gene transcription (8, 9, 14, 15, 21). The
p38a MAPK system can also increase
cytokine production through post-tran-
scriptional mechanisms of mRNA
stabilization or translation through p38-
MAPK-activated protein kinase 2 (MK2)
stress-activated pathways (21, 32). In addi-
tion, p38a MAPK controls the synthesis of
other compounds, including chemokines,
metalloproteinases and prostaglandins (16).
LPS-induced events leading to IL-6 pro-
duction in periodontal ligament (PDL) cells
has not been described. These studies
indicate that although all MAPK pathways
are involved in LPS-induced IL-6 produc-
tion, p38a MAPK is the predominant




Murine periodontal ligament (mPDL) fi-
broblasts immortalized with simian virus
40 large T antigen were obtained from Dr
Martha Somerman (University of Wash-
ington, Seattle, WA). Stable mPDLs con-
taining MKK-3 dominant-negative (DN)
and MKK-6 DN mPDL stable cell lines
were as described previously (22). Mouse
embryonic fibroblasts (MEF), both wild-
type and p38a)/), were obtained by
material transfer from Dr Angel Nebreda,
Madrid, Spain. The p38a null MEFs were
obtained by targeted deletion of the p38a
ene and subsequent isolation of fibroblasts
established from E11.5–E12.5 embryos
(1). All cells were cultured with Dul-
becco’s modified Eagle’s medium (Invi-
trogen, Carlsbad, CA) supplemented with
10% heat inactivated fetal bovine serum,
100 IU/ml penicillin, 100 lg/ml strepto-
mycin in an incubator at 37C in 5% CO2.
IL-1b and Escherichia coli LPS were
obtained from R & D Systems, Inc.
(Minneapolis, MN) and Sigma Aldrich
(St Louis, MO), respectively. The
A. actinomycetemcomitans LPS serotype
b was purified and obtained from strain Y4
as described elsewhere (29–31). Biochemi-
cal inhibitors SB203580 (water-soluble),
SP600125 (dimethyl sulfoxide [DMSO]
soluble), and PD98059 (DMSO soluble)
were obtained from Calbiochem (San
Diego, CA). The final DMSO concentra-
tion used in all experimental protocols was
0.01% (v/v). Controls used included
DMSO at the final concentration used to
dissolve SP600125 and PD98059.
Immunoblot analysis
Whole cell lysates were harvested by
scraping the cells on SDS sample buffer
(62.5 mm Tris–HCl buffer pH 6.8, 10%
glycerol, 50 mm dithiothreitol, 2% sodium
dodecyl sulfate, 0.01% bromophenol blue)
on ice, sonicated for 10 s and heat-dena-
tured at 95C for 5 min. Western blot
analysis was performed as described pre-
viously (22), proteins were separated on
10% Tris–HCl polyacrylamide gels run at
150 V for 50 min and subsequently elec-
tro-transferred for another 45 min at
32 mA in a semi-dry apparatus to nitro-
cellulose membranes. The membranes
were blocked (Tris-buffered saline with
5% non-fat dry milk, 0.1% Tween-20) for
1 h at room temperature and then probed
overnight at 4C with primary antibodies.
Primary antibodies for phosphorylated
p38, JNK and ERK MAPK were from
Cell Signaling (Danvers, MA), as well as
the secondary horseradish peroxidase-con-
jugated antibodies. The GAPDH primary
antibody was obtained from Chemicon
(Temecula, CA). The presence of the
primary antibodies was detected on radio-
graphic film by using horseradish peroxi-





Total RNA was isolated from cells using
TRIZOL (Invitrogen) according to the
manufacturer’s instructions. Total RNA
was resuspended in Tris–ethylenediamine-
tetraacetic acid (TE, pH 7.0). RNA was
quantified at an optical density of 260 nm
(OD260) using a Beckman DU-600 spec-
trophotometer. RT-PCR was used to ana-
lyse mRNA expression as described
previously. Briefly, cDNAwas synthesized
by a RT kit (Applied Biosystems, Foster
City, CA) using 300 ng total RNA in a
15 ll reaction. Each reaction contained
1.5 ll RT-buffer, 3.3 ll 25 mm MgCl2,
3 ll 10 mm dNTP, 0.75 ll oligo-dT, 0.3 ll
RNAse inhibitor, 0.37 ll of Multiscribe
reverse transcriptase, and 3.77 ll DNAse/
RNAse-free H2O. RT thermocycler condi-
tions were as follows: 25C for 10 min,
48C for 30 min, and 95C for 5 min. A 2-
ll subsample of the RT product was then
used in 25-ll PCR. The PCR mix con-
tained nuclease-free water, 0.125 ll Taq
polymerase, 1.5 mm MgCl2, 20 pm sense/
antisense primer, and 0.5 ll 12.5 mm
dTNP. The PCR thermocycler (iCyclerTM
Thermocycler, BioRad, Hercules, CA)
conditions used were as follows: 95C for
5 min, and 35 cycles of 95C for 1 min,
58C (IL-6) or 52C (glyceraldehyde-3-
phosphate dehydrogenase [GAPDH]) for
2 min, and 72C for 1 min followed by a
10-min elongation phase at 72C. Ampl-
icon primers were used for murine IL-6
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(accession no. NM_031168.1, forward
5¢-atgaagttcctctctgcaagagact-3¢ and reverse
5¢-cactaggtttgccgagtagatctc-3¢) and murine
GAPDH (accession no. NM_008084, for-
ward 5¢-caccatggagaaggccgggg-3¢and
reverse 5¢-gacggacacattgggggtag-3¢). PCR
products were run on a 1% agarose gel
containing 0.5 lg/ml ethidium bromide.
IL-6 levels were quantified and normalized
to GAPDH levels using densitometric
analysis on a BioRad Gel-Doc system and
BioRad Quantity One software.
Enzyme-linked immunosorbent assay
(ELISA)
PDL cells were plated at 5 · 104 cells/well
in 24-well dishes and stimulated with
A. actinomycetemcomitans LPS (5 lg/
ml), E. coli LPS (5 lg/ml), or IL-1b
(5 ng/ml) for 24 h. To determine the
MAPK pathways involved, cells were
pretreated for 1 h with SB203580,
SP600125 and PD98059 (all at 10 lm)
and stimulated. Vehicle-only and inhibitor-
only cultures served as controls. Cell
culture supernatants were harvested using
an mIL-6 ELISA following the manufac-
turer’s instructions (R & D Systems Inc.).
Statistical analysis
All data were subjected to statistical
analysis through appropriate analysis para-
meters. Student’s t-tests were used to
obtain individual P-values when appropri-
ate and two-way analysis of variance
(anova) was used when multifactorial
statistical analysis was needed. Two-way
anova with Bonferroni post-tests and
two-tailed paired Student’s t-tests were
performed using Graphpad Prism ver-
sion 4.03 for Windows, Graphpad Soft-
ware, San Diego, CA.
Results
MAPK pathways are rapidly activated in
mPDL cells
Treatment with A. actinomycetemcomitans
LPS, E. coli LPS and IL-1b resulted in
phosphorylation of the ERK and p38
MAPK pathways (Fig. 1); A. actinomyce-
temcomitans LPS and IL-1b additionally
activated JNK MAPK. These data indicate
the rapid kinetics (within 10 min) of
MAPK activation in mPDL cells.
Inflammatory stimuli induce IL-6 mRNA
production in mPDL cells
Initial studies were conducted in mPDL
cells to determine the time-course and
dose-response of IL-6 mRNA expression
in response to A. actinomycetemcomitans
LPS, E. coli LPS, and IL-1b. Time-course
of IL-6 mRNA induction experiments
revealed that the optimal induction time
for IL-6 mRNA was 18 h poststimulation
(Fig. 2A). All inflammatory stimuli pro-
duced a bi-phasic induction of IL-6
mRNA, however, E. coli LPS and IL-1b
induced similar temporal kinetic expres-
sion profiles of IL-6 mRNA. At the 18-h
time-point the mean (n ¼ 3) fold induction
of IL-6 was 2.7 with IL-1b (P ¼ 0.0267;
paired t-test), 2.23 with E. coli LPS
P ¼ 0.0055; paired t-test) and 2.01 with
A. actinomycetemcomitans LPS stimula-
tion (P ¼ 0.001; paired t-test). Consistent
with the IL-6 mRNA levels, IL-6 protein
expression increased in a similar time-
dependent manner (Fig. 2B). At the 18-h
and 24-h time-points, significant eleva-
tions in IL-6 protein were observed from
time 0 in response to IL-1b, E. coli LPS
and A. actinomycetemcomitans LPS sti-
mulation (n ¼ 3).
Dose–response analysis revealed the
optimal stimulus concentration to be
5 lg/ml for both A. actinomycetemcomi-
tans LPS and E. coli LPS while it was
5 ng/ml for IL-1b (n ¼ 3) (Fig. 2C).
Interestingly, A. actinomycetemcomitans
and E. coli LPS 10 lg/ml provided satur-
ated expression of IL-6 mRNA. This effect
was also observed for IL-1b at 10 ng/ml.
Optimal time and dose were utilized in all
subsequent experiments.
MAPK signaling pathways involved in
LPS-induced IL-6 expression
Next, we evaluated the MAPK signaling
pathways involved in the induction of IL-
6 production by IL-1b, E. coli LPS and
A. actinomycetemcomitans LPS at the
mRNA and protein levels. Major MAPK
signaling pathways evaluated included
ERK, JNK and p38a MAPK. The path-
ways were inhibited using specific bio-
chemical inhibitors PD98059 (ERK),
SP600125 (JNK) and SB203580 (p38
MAPK). The RT-PCR was performed on
RNA isolated 18 h post treatment
(n ¼ 3). SB203580 (10 lm) inhibited all
inflammatory stimuli greatly, while
SP600125 (10 lm) and PD98059
(10 lm) inhibition varied among inflam-
matory stimuli (Fig. 3A,B). SB203580
was able to reduce IL-6 mRNA produc-
tion by >70% for A. actinomycetemcom-
itans LPS treatment (P < 0.001; two-way
anova), >95% for E. coli LPS treatment
(P < 0.05; two-way anova, and 60%
from IL-1b treatment (P < 0.05; two-way
anova). SP600125 and PD98059 had the
greatest inhibitory effects (50%;
P < 0.05; two-way anova) with E. coli
LPS and IL-1b treatments.
IL-6 ELISAwas performed to determine
if the effects of the biochemical inhibitors
translated to the protein level (Fig. 4).
Murine PDL cells were treated as des-
cribed above. Cell culture supernatants
were harvested 24 h post-treatment and
IL-6 ELISA was performed (n ¼ 4). Sti-
mulation with each of the inflammatory
stimuli produced copious IL-6 when com-
pared to untreated cultures. Specifically
A. actinomycetemcomitans LPS and IL-1b
induced >500 pg/ml IL-6, while E. coli
induced >450 pg/ml IL-6. SB203580 (p38
MAPK inhibitor) and SP600125 (JNK
inhibitor) provided the greatest inhibition
of inducible IL-6 production in response to
inflammatory agonists. PD98059 (ERK
inhibitor) provided comparable inhibition
when cells were stimulated with E. coli
LPS or IL-1b. B203580 (p38 MAPK
inhibitor) reduced IL-6 production by all
Fig. 1. IL-1b, Escherichia coli and Actinoba-
cillus actinomycetemcomitans (Aa) LPS stimu-
lation rapidly activates ERK, p38 and JNK
MAPK. Mouse PDL cells were stimulated with
IL-1b (5 ng/ml), E. coli LPS (5 lg/ml) or A.
actinomycetemcomitans LPS (5 lg/ml) for
30 min. Immunoblot analysis using whole cell
lysates (15 lg) indicated that ERK and p38
MAPK pathways are activated by LPS whereas
A. actinomycetemcomitans LPS and IL-1b acti-
vate JNK. A representative experiment shown
from five experiments.
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agonists by >60%, but the greatest
decrease was observed in cells treated
with A. actinomycetemcomitans LPS. The
effect of SP600125 was observed mostly
with E. coli LPS and IL-1bs the inhibitor
reduced IL-6 production P70%. PD98059
was capable of inhibiting IL-1b- and E.
coli LPS-induced IL-6, but was unable to
inhibit A. actinomycetemcomitans LPS-
induced levels equivalent to that of
SB203580.
MKK-3/6-p38a MAPK pathway is required
for IL-6 expression
Biochemical inhibitors provide relatively
specific inhibition of their respective sign-
aling pathways. However, to verify the
role of p38 MAPK in IL-6 production,
stable mPDL cells over-expressing DN
MKKs, which directly phosphorylate p38,
were employed. MKK-3 and MKK-6 DN
stable mPDL cells were utilized, along
with mock-transfected (empty vector)
mPDL cells (n ¼ 3). Cells were stimulated
with A. actinomycetemcomitans LPS, E.
coli LPS and IL-1b as described above
(Figs 4B and 5A). Eighteen hours post
stimulation, total RNA was isolated and
IL-6 steady-state mRNA levels were meas-
ured. In MKK-3 DN cells IL-6 mRNA
expression was statistically reduced in all
stimulated cultures (P < 0.05 for A. actin-
omycetemcomitans LPS and P < 0.001 for
E. coli LPS and IL-1b; two-way anova).
MKK-6 DN cells significantly reduced the
fold change of IL-6 mRNA in E. coli LPS
(P < 0.01; two-way anova) and IL-1b
only (P < 0.001; two-way anova). In
both MKK-3 and MKK-6 DN cells, the
greatest reduction of IL-6 mRNA was
observed when cells were treated with
IL-1b. These data suggest that while IL-1b
and E. coli LPS activate p38 MAPK-
induced IL-6 mRNA through MKK-3 and
MKK-6, A. actinomycetemcomitans LPS
activates p38 MAPK predominantly
through MKK-3.
To further validate the need for an intact
p38 signaling system for A. actinomyce-
temcomitans LPS-induced IL-6 expres-
sion, MEFs with targeted disruption of
the p38a gene were used. The A. actin-
omycetemcomitans LPS induced over
300 pg/ml (P < 0.001) of IL-6 in wild-
type MEFs while in p38a)/) MEFs, IL-6
production was not significant (P < 0.001)
compared to the untreated controls
(Fig. 6). Lack of p38a reduced the amount
of IL-6 induced by A. actinomycetemcom-
itans LPS by 90% (P < 0.001; two-way
anova).
Discussion
Periodontal diseases are characterized by
loss of alveolar bone, a process mediated
by osteoclasts. Locally abundant LPS




Fig. 2. IL-1b, Escherichia coli and Actinobacillus actinomycetemcomitans (Aa) LPS induce IL-6
mRNA. (A) Murine PDL cells were grown to near confluence and serum starved in 0.3% fetal bovine
serum media for 6 h. Cells were then stimulated with A. actinomycetemcomitans LPS, E. coli LPS,
and IL-1b for 2, 4, 8 and 18 h at doses as high as 10 ng/ml for IL-1b, and 10 lg/ml for both A.
actinomycetemcomitans LPS and E. coli LPS. Total RNA was isolated and RT-PCR was performed
measuring IL-6 normalized to GAPDH. Maximum IL-6 mRNA production plateaued at 5 ng/ml for
IL-1b, and 5 lg/ml for both A. actinomycetemcomitans LPS and E. coli LPS. (B) Murine PDL cells
were grown in the same manner as in (A) with cell culture supernatants harvested at the indicated
time-points for IL-6 protein determination by ELISA. The results represent the mean pg/ml ± SE
(n ¼ 3). Significant induction of IL-6 was observed at 18 and 24 h (C). The results represent the
mean fold induction ±SE (n ¼ 3) for both panels. P-values were obtained using paired two-tailed
Student’s t-tests. P-values were derived comparing stimulant to control (no treatment), *P < 0.05
was considered statistically significant.
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largely responsible for the increased
resorption of bone. LPS can stimulate the
production of osteoblastic IL-1b, TNF-a,
IL-6 and receptor activator of NF-kB
ligand (RANKL) directly or indirectly
(11, 13, 19). Sources of IL-6 in the
periodontium include periodontal and gin-
gival fibroblasts, macrophages, lympho-
cytes and osteoblasts (25, 26). However,
the PDL fibroblast is poised in position to
play a significant role in IL-6 production in
chronic periodontitis. Inhibition of IL-6
expression presents an attractive target for
the treatment of chronic inflammatory
bone disease states. Thus, understanding
IL-6 regulation in PDL fibroblasts may be
critical for inflammatory-cytokine-based
therapies in the management of periodon-
tal diseases. In this report, MAPK signa-
ling pathways induced by LPS that were
required for IL-6 expression in PDL
fibroblasts were analysed through bio-
chemical inhibitors, MKK DN stable cell
lines, and p38 knock-out cell models. The
data indicate that A. actinomycetemcomi-
tans LPS induction of IL-6 uses multiple
MAPK pathways but predominantly the
MKK-3-p38 pathway in mPDL fibroblasts.
Numerous studies have analysed perio-
dontal pathogens and their constituents to
produce pro-inflammatory cytokines.
Extracts from A. actinomycetemcomitans
have been able to induce IL-8 in gingival
epithelial cells independent of LPS (24).
Comparison studies evaluating the ability
of E. coli LPS and Porphyromonas gingi-
valis to induce IL-6, IL-8, IL-10 and IL-12
in dendritic cells found E. coli LPS to be
the more potent agonist (12). In the present
study, the prototypical E. coli LPS was
used as a relative comparison to A. actin-
omycetemcomitans LPS. Along with
E. coli, the A. actinomycetemcomitans-
derived LPS has been demonstrated to
induce IL-1b, IL-6 and TNF-a in human
monocytes (3).
Our results support other studies that
have shown a similar plateau in IL-6
expression by E. coli LPS in monocytes
and bone-marrow-derived macrophages
(17, 18). The A. actinomycetemcomitans
LPS also had the same kind of response as
E. coli LPS. This effect may emphasize a
conserved mechanism of activation during
LPS-induced inflammation. Although IL-6
mRNA production was statistically signi-
ficant as early as 2 h with A. actinomyce-
temcomitans LPS, E. coli LPS and IL-1b,
maximal steady-state IL-6 expression was
not reached until 18 h in mPDL cells. The
ability of inflammatory stimuli to induce
IL-6 after 2 h suggests that there is direct
stimulation of IL-6 because de novo protein
A
B
Fig. 3. IL-6 requires predominantly p38a MAPK when stimulated by IL-1b, Actinobacillus
actinomycetemcomitans (Aa) and Escherichia coli LPS. Murine PDL cells were grown to near
confluence and serum starved with 0.3% FBS media for 6 h. Cells were pretreated with inhibitors
specific for ERK (PD98059), JNK (SP600125), and p38a MAPK (SB203580) pathways at a
concentration of 10 lm and stimulated with IL-1b (5 ng/ml) and LPS (5 lg/ml) from
A. actinomycetemcomitans and E. coli. Total RNA was harvested after 18 h and RT-PCR was
performed measuring IL-6 fold induction compared to GAPDH. (A) Representative gel from
RT-PCR analysis. (B) Graphical representation of results showing mean fold induction ±SE (n ¼ 3).
Using two-way anova, P-values were derived comparing stimulant to control (no treatment),
*P < 0.05 was considered statistically significant.
Fig. 4. p38a MAPK and JNK pathway are needed for Actinobacillus actinomycetemcomitans (Aa)
LPS secretion of IL-6. Murine PDL cells were grown to near confluence then serum starved with
0.3% fetal bovine serum media for 6 h. Cells were treated with inhibitors and after 1 h cells were
treated with inflammatory stimuli as described in Fig. 2. Twenty-four hours after treatment,
supernatants were collected and ELISA detection of IL-6 protein was measured. The results represent
the mean pg/ml ± SE (n ¼ 3). Two-way anova was utilized to generate P-values. P-values compare
inhibitor to stimulant (no inhibitor), *P values compare stimulant to control (no treatment), or
*P<0.05 was considered statistically significant.
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synthesis has not occurred. At 18 h, IL-6
may be stimulated by multiple cytokines,
acting in an autocrine manner, thus indi-
rectly activating and amplifying inflamma-
tory stimulus-induced IL-6 expression.
Surprisingly, when PDL cells were trea-
ted with biochemical inhibitors alone, the
data indicate that SP600125 (the JNK
inhibitor) significantly increased IL-6
mRNA induction when compared to vehi-
cle control. In previous experiments, we
have observed that SP600125 (JNK inhib-
itor) and PD98059 (ERK inhibitor)
increase basal phosphorylated p38 MAPK
levels in mPDL cell lysates (22). IL-6
mRNA appeared to be induced predomin-
antly through p38 MAPK for all inflam-
matory stimuli. However, p38 and JNK
appeared to be equally involved in
A. actinomycetemcomitans LPS secretion
of IL-6. All biochemical inhibitors reduced
IL-1b and E. coli LPS-induced IL-6 secre-
tion. The discrepancies observed between
IL-6 mRNA and protein inhibition are most
likely the result of differences in IL-6
protein and mRNA half-lives (14).
The present study evaluated only the
contribution of MAPK towards LPS-
induced IL-6 expression; however, IL-6
contains AP-1 (activator protein 1) and
NF-IL-6 transcription factor binding re-
gions, which directly implicates NF-jB in
the production of IL-6. In the light of this,
we cannot rule out the involvement of NF-
jB in the production of IL-6. Initial studies
using a NF-jB inhibitor indicated partial
inhibition of LPS-induced IL-6 (data not
shown). In mouse fibrosarcoma cells,
TNF-a-induced, NF-jB-stimulated IL-6
gene expression requires both p38a
MAPK and ERK. When activated, p38a
MAPK can activate NF-jB pathways
through TNF receptor-associated factor-6
(27). It is well established that p38 is
phosphorylated by upstream kinases
MKK-3 or MKK-6 (5). Dominant negative
isoforms of both MKK-3 and -6 have been
shown to have reduced kinase activity on
p38a MAPK substrates (4).
The A. actinomycetemcomitans LPS
preferentially utilized MKK-3/p38a acti-
vation for IL-6 mRNA expression. Inter-
estingly, preferential activation of p38a by
either MKK-3 or MKK-6 has been ob-
served by others. Inoue et al. observed that
MKK-3 plays a greater role in cytokine
and MMP expression in fibroblast-like
synoviocytes from patients with rheuma-
toid arthritis (10). Osmotic shock and
TNF-induced expression of cytokines has
been reduced in MKK-3)/) MEF (33). Our
group has recently shown that MKK-6/p38
is important for LPS-induced MMP-13
expression is mPDL fibroblasts (Carlos
Rossa, Jr., Paul M. Bronson, Min Liu,
Keith L. Kirkwood, unpublished data).
However, in the present study IL-1b and E.
coli LPS utilized both MKK-3 and MKK-6
pathways with no statistically significant
preference between either MKK.
One limitation of our stable cells is that
either MKK-3 DN or MKK-6 DN is
expressed, not both. As a consequence of
blocking MKK-3 or MKK-6 activation of
p38a MAPK can still occur through
MKK-3 or MKK-6 phosphorylation. To
address this, the role of p38a in
A. actinomycetemcomitans LPS induction
of IL-6 was extended with the use of MEF
wild-type and p38a)/) cells. In p38a
MAPK)/) MEF cells, A. actinomycetem-
comitans LPS-induced IL-6 was signifi-
A
B
Fig. 5. MKK-3-induced-p38a MAPK is utilized in IL-1b, Actinobacillus actinomycetemcomitans
(Aa) LPS, and E. coli LPS induction of IL-6 mRNA. Wild-type, MKK-3 and MKK-6 DN stable
mouse PDL cells were serum starved with 0.3% fetal bovine serum media for 6 h then stimulated
with IL-1b 5 ng/ml), A. actinomycetemcomitans LPS (5 lg/ml), and E. coli LPS (5 lg/ml). Total
RNA was isolated 18 h later and RT-PCR was performed. IL-6 was compared to GAPDH and IL-6
fold induction was determined. (A) Representative gel from RT-PCR analysis. (B) Graphical
representation of results showing the mean fold induction ±SE (n ¼ 3). Two-way anova was
utilized to generate P-values. P-values compare DN stable cell lines to mPDL cells. *P-values
compare stimulant to control (no treatment), or *P < 0.05 was considered statistically significant.
Fig. 6. p38a MAPK is necessary for IL-6
protein expression in MEF cells. Wild-type
(WT) and p38a)/) MEF cells were grown
plated and grown to near confluence. Cells were
then serum starved with 0.3% fetal bovine
serum media for 6 h followed by treatment with
Actinobacillus actinomycetemcomitans LPS
(5 lg/ml). After 24 h, supernatants were isola-
ted and ELISA was performed measuring IL-6
protein. The results represent the mean pg/
ml ± SE (n ¼ 3). Two-way anova was utilized
to generate P-values. P-values compare wild-
type to p38a MAPK)/) MEF3T3 cells.
*P-values compare stimulant to control (no
treatment), or *P < 0.05 was considered
statistically significant.
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cantly reduced when compared to wild-type
cells, suggesting that p38a is a vital sign-
aling intermediate required for IL-6 expres-
sion. Interestingly, E. coli LPS was unable
to induce IL-6 protein expression in either
wild-type or p38a)/) cells but IL-1b effects
were similar to those observed with
A. actinomycetemcomitans LPS (data not
shown). An additional limitation is that the
data presented are from using p38)/) MEF
cells, which are clearly not PDL cells. PDL
cells cannot be obtained from p38)/) mice
because these mice die in utero. The MEF
cells were harvested between E11.5–12.5
and PDL tissue fibers that support the tooth
and bone form approximately day 27 post-
conception, so PDL cells from the p38)/)
mice cannot be obtained (M. Somerman,
personal communication).
In summary, A. actinomycetemcomitans
LPS-induced IL-6 expression requires
p38a MAPK pathway signaling in PDL
fibroblasts. IL-6 is a key pro-inflammatory
cytokine capable of stimulating osteoclast-
ogenesis in coupled bone turnover via
induction of RANKL. Our group has
recently established that TNF-a and
IL-1b-induced RANKL in bone marrow
stromal cells requires p38 MAPK (23).
Importantly, parathyroid hormone and
1,25(OH)2-vitamin D3-induced RANKL
are unaffected by p38 inhibitors, support-
ing the role of p38 antagonists to block
inflammation-stimulated bone loss while
sparing physiological bone turnover. Thus,
because p38 MAPK is a key signaling
intermediate utilized by LPS and IL-1-
induced IL-6 expression in PDL fibro-
blasts, targeting p38 MAPK may have
therapeutic importance for the manage-
ment of chronic periodontitis.
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